Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab as Consolidative Therapy for Waldenstrom Macroglobulinemia
NCT07882173Phase 2Not yet recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in Waldenstrom macroglobulinemia (WM), sponsored by National Heart, Lung, and Blood Institute. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07882173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882173.